High intravitreal TGF-β1 and MMP-9 levels in eyes with retinal vein occlusion

Purpose Vascular endothelial growth factor is a leading target to reduce macular oedema and improve visual acuity in patients with retinal vein occlusion (RVO), whereas the role of vascular destabilizing and fibroproliferative transforming growth factor (TGF)- β 1 and matrix metalloproteinases (MMP)...

Full description

Saved in:
Bibliographic Details
Published in:Eye (London) 2014-09, Vol.28 (9), p.1095-1099
Main Authors: Tuuminen, R, Loukovaara, S
Format: Article
Language:English
Subjects:
692/53
692/699/3161/3175
692/700/565/545
Aged
Biomarkers - metabolism
Clinical Study
Enzyme-Linked Immunosorbent Assay
Female
Humans
Laboratory Medicine
Male
Matrix Metalloproteinase 9 - metabolism
Medicine
Medicine & Public Health
Middle Aged
Ophthalmology
Pharmaceutical Sciences/Technology
Prospective Studies
Retinal Neovascularization - metabolism
Retinal Neovascularization - surgery
Retinal Vein Occlusion - metabolism
Retinal Vein Occlusion - surgery
Surgery
Surgical Oncology
Transforming Growth Factor beta1 - metabolism
Vitrectomy
Vitreous Body - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Vascular endothelial growth factor is a leading target to reduce macular oedema and improve visual acuity in patients with retinal vein occlusion (RVO), whereas the role of vascular destabilizing and fibroproliferative transforming growth factor (TGF)- β 1 and matrix metalloproteinases (MMP)-2 and -9 in pathological manifestations of RVO is anticipated but less studied. Methods Undiluted vitreous samples were collected from three central RVO and one branch RVO eyes, all with neovascularization and fibrosis-related sight-threatening complications of RVO. Undiluted vitreous samples of 40 eyes operated due to non-ischemic condition either macular hole or pucker were used as controls. Growth factor and protease concentrations were measured by ELISA and gelatin zymography. Results Vitreous concentrations of TGF- β 1 (92.0±17.4 pg/ml vs 18.3±27.0 pg/ml, mean±SD; P =0.002) and MMP-9 (847.9±1196.4 AU/ml vs 87.7±174.0 AU/ml; P =0.010) were higher in the eyes with ischemic RVO than in the controls. Conclusions High intravitreal levels of TGF- β 1 and MMP-9 are found in RVO eyes having neovascular and fibrosis manifestation. Further studies are warranted to elucidate whether targeting TGF- β 1 and MMP-9 could be beneficial in patients with ischemic RVO.
ISSN:0950-222X
1476-5454
DOI:10.1038/eye.2014.137